nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefixime—Blister—Mechlorethamine—lymphatic system cancer	0.0341	0.0341	CcSEcCtD
Cefixime—Nephropathy toxic—Teniposide—lymphatic system cancer	0.0315	0.0315	CcSEcCtD
Cefixime—Meningitis—Carmustine—lymphatic system cancer	0.0263	0.0263	CcSEcCtD
Cefixime—Nephropathy toxic—Bleomycin—lymphatic system cancer	0.0203	0.0203	CcSEcCtD
Cefixime—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.0198	0.0198	CcSEcCtD
Cefixime—Dermatitis bullous—Mechlorethamine—lymphatic system cancer	0.0187	0.0187	CcSEcCtD
Cefixime—Nephropathy toxic—Carmustine—lymphatic system cancer	0.0177	0.0177	CcSEcCtD
Cefixime—Nephropathy toxic—Mitoxantrone—lymphatic system cancer	0.0165	0.0165	CcSEcCtD
Cefixime—Hepatic function abnormal—Teniposide—lymphatic system cancer	0.015	0.015	CcSEcCtD
Cefixime—Pancytopenia—Mechlorethamine—lymphatic system cancer	0.0146	0.0146	CcSEcCtD
Cefixime—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.0146	0.0146	CcSEcCtD
Cefixime—Jaundice—Mechlorethamine—lymphatic system cancer	0.0134	0.0134	CcSEcCtD
Cefixime—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0128	0.0128	CcSEcCtD
Cefixime—Haemoglobin—Mechlorethamine—lymphatic system cancer	0.0124	0.0124	CcSEcCtD
Cefixime—Haemorrhage—Mechlorethamine—lymphatic system cancer	0.0123	0.0123	CcSEcCtD
Cefixime—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0117	0.0117	CcSEcCtD
Cefixime—Pancytopenia—Teniposide—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Cefixime—Neutropenia—Teniposide—lymphatic system cancer	0.0106	0.0106	CcSEcCtD
Cefixime—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.0104	0.0104	CcSEcCtD
Cefixime—Blood bilirubin increased—Mitoxantrone—lymphatic system cancer	0.01	0.01	CcSEcCtD
Cefixime—Candida infection—Carmustine—lymphatic system cancer	0.00973	0.00973	CcSEcCtD
Cefixime—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00961	0.00961	CcSEcCtD
Cefixime—Pancytopenia—Fludarabine—lymphatic system cancer	0.00948	0.00948	CcSEcCtD
Cefixime—Neutropenia—Fludarabine—lymphatic system cancer	0.00934	0.00934	CcSEcCtD
Cefixime—Haemoglobin—Teniposide—lymphatic system cancer	0.00914	0.00914	CcSEcCtD
Cefixime—Haemorrhage—Teniposide—lymphatic system cancer	0.00909	0.00909	CcSEcCtD
Cefixime—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00883	0.00883	CcSEcCtD
Cefixime—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00876	0.00876	CcSEcCtD
Cefixime—Renal failure—Fludarabine—lymphatic system cancer	0.00875	0.00875	CcSEcCtD
Cefixime—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00865	0.00865	CcSEcCtD
Cefixime—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00858	0.00858	CcSEcCtD
Cefixime—Haemoglobin—Fludarabine—lymphatic system cancer	0.00803	0.00803	CcSEcCtD
Cefixime—Haemorrhage—Fludarabine—lymphatic system cancer	0.00799	0.00799	CcSEcCtD
Cefixime—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00756	0.00756	CcSEcCtD
Cefixime—Renal failure acute—Mitoxantrone—lymphatic system cancer	0.00745	0.00745	CcSEcCtD
Cefixime—Face oedema—Carmustine—lymphatic system cancer	0.00714	0.00714	CcSEcCtD
Cefixime—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.0071	0.0071	CcSEcCtD
Cefixime—Leukopenia—Teniposide—lymphatic system cancer	0.00709	0.00709	CcSEcCtD
Cefixime—Pancytopenia—Bleomycin—lymphatic system cancer	0.00695	0.00695	CcSEcCtD
Cefixime—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00646	0.00646	CcSEcCtD
Cefixime—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00633	0.00633	CcSEcCtD
Cefixime—Leukopenia—Fludarabine—lymphatic system cancer	0.00623	0.00623	CcSEcCtD
Cefixime—Pruritus—Mechlorethamine—lymphatic system cancer	0.0062	0.0062	CcSEcCtD
Cefixime—Pancytopenia—Carmustine—lymphatic system cancer	0.00607	0.00607	CcSEcCtD
Cefixime—Convulsion—Fludarabine—lymphatic system cancer	0.00603	0.00603	CcSEcCtD
Cefixime—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.006	0.006	CcSEcCtD
Cefixime—Neutropenia—Carmustine—lymphatic system cancer	0.00598	0.00598	CcSEcCtD
Cefixime—Haemoglobin—Bleomycin—lymphatic system cancer	0.00589	0.00589	CcSEcCtD
Cefixime—Haemorrhage—Bleomycin—lymphatic system cancer	0.00586	0.00586	CcSEcCtD
Cefixime—Pancytopenia—Vincristine—lymphatic system cancer	0.00579	0.00579	CcSEcCtD
Cefixime—Neutropenia—Vincristine—lymphatic system cancer	0.0057	0.0057	CcSEcCtD
Cefixime—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00568	0.00568	CcSEcCtD
Cefixime—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00564	0.00564	CcSEcCtD
Cefixime—Renal failure—Carmustine—lymphatic system cancer	0.0056	0.0056	CcSEcCtD
Cefixime—Vomiting—Mechlorethamine—lymphatic system cancer	0.00557	0.00557	CcSEcCtD
Cefixime—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00556	0.00556	CcSEcCtD
Cefixime—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00556	0.00556	CcSEcCtD
Cefixime—Urinary tract infection—Carmustine—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Cefixime—Rash—Mechlorethamine—lymphatic system cancer	0.00553	0.00553	CcSEcCtD
Cefixime—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00552	0.00552	CcSEcCtD
Cefixime—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00528	0.00528	CcSEcCtD
Cefixime—Renal failure—Mitoxantrone—lymphatic system cancer	0.00521	0.00521	CcSEcCtD
Cefixime—Nausea—Mechlorethamine—lymphatic system cancer	0.00521	0.00521	CcSEcCtD
Cefixime—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.00519	0.00519	CcSEcCtD
Cefixime—Jaundice—Mitoxantrone—lymphatic system cancer	0.00516	0.00516	CcSEcCtD
Cefixime—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00515	0.00515	CcSEcCtD
Cefixime—Haemoglobin—Carmustine—lymphatic system cancer	0.00514	0.00514	CcSEcCtD
Cefixime—Urticaria—Teniposide—lymphatic system cancer	0.00513	0.00513	CcSEcCtD
Cefixime—Haemorrhage—Carmustine—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Cefixime—Abdominal pain—Teniposide—lymphatic system cancer	0.00511	0.00511	CcSEcCtD
Cefixime—Body temperature increased—Teniposide—lymphatic system cancer	0.00511	0.00511	CcSEcCtD
Cefixime—Dyspepsia—Fludarabine—lymphatic system cancer	0.005	0.005	CcSEcCtD
Cefixime—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00494	0.00494	CcSEcCtD
Cefixime—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00478	0.00478	CcSEcCtD
Cefixime—Hypersensitivity—Teniposide—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Cefixime—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Cefixime—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00476	0.00476	CcSEcCtD
Cefixime—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00472	0.00472	CcSEcCtD
Cefixime—Pruritus—Teniposide—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Cefixime—Leukopenia—Bleomycin—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Cefixime—Body temperature increased—Fludarabine—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Cefixime—Vaginal infection—Methotrexate—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Cefixime—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Cefixime—Diarrhoea—Teniposide—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Cefixime—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00418	0.00418	CcSEcCtD
Cefixime—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Cefixime—Vomiting—Teniposide—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Cefixime—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Cefixime—Rash—Teniposide—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Cefixime—Dermatitis—Teniposide—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Cefixime—Headache—Teniposide—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Cefixime—Pruritus—Fludarabine—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Cefixime—Leukopenia—Carmustine—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Cefixime—Diarrhoea—Fludarabine—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Cefixime—Convulsion—Carmustine—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Cefixime—Nausea—Teniposide—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Cefixime—Leukopenia—Vincristine—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Cefixime—Renal failure acute—Methotrexate—lymphatic system cancer	0.00371	0.00371	CcSEcCtD
Cefixime—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00371	0.00371	CcSEcCtD
Cefixime—Convulsion—Vincristine—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Cefixime—Vomiting—Fludarabine—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Cefixime—Convulsion—Mitoxantrone—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Cefixime—Rash—Fludarabine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Cefixime—Dermatitis—Fludarabine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Cefixime—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Cefixime—Headache—Fludarabine—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Cefixime—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Cefixime—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Cefixime—Thrombocytopenia—Vincristine—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Cefixime—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Cefixime—Nausea—Fludarabine—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Cefixime—Shock—Mitoxantrone—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Cefixime—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Cefixime—Urticaria—Bleomycin—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Cefixime—Body temperature increased—Bleomycin—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Cefixime—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Cefixime—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Cefixime—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Cefixime—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Cefixime—Pruritus—Bleomycin—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Cefixime—Eosinophilia—Methotrexate—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Cefixime—Abdominal pain—Carmustine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Cefixime—Body temperature increased—Carmustine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Cefixime—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Cefixime—Pancytopenia—Methotrexate—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Cefixime—Neutropenia—Methotrexate—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Cefixime—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Cefixime—Abdominal pain—Vincristine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Cefixime—Body temperature increased—Vincristine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Cefixime—Urticaria—Mitoxantrone—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Cefixime—Hypersensitivity—Carmustine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Cefixime—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Cefixime—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Cefixime—Vomiting—Bleomycin—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Cefixime—Rash—Bleomycin—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Cefixime—Dermatitis—Bleomycin—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Cefixime—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Cefixime—Renal failure—Methotrexate—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Cefixime—Hypersensitivity—Vincristine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Cefixime—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Cefixime—Diarrhoea—Carmustine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Cefixime—Nausea—Bleomycin—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Cefixime—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Cefixime—Dizziness—Carmustine—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Cefixime—Haemoglobin—Methotrexate—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Cefixime—Diarrhoea—Vincristine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Cefixime—Hepatitis—Methotrexate—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Cefixime—Haemorrhage—Methotrexate—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Cefixime—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Cefixime—Vomiting—Carmustine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Cefixime—Dizziness—Vincristine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Cefixime—Rash—Carmustine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Cefixime—Dermatitis—Carmustine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Cefixime—Headache—Carmustine—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Cefixime—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Cefixime—Vomiting—Vincristine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Cefixime—Rash—Vincristine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Cefixime—Dermatitis—Vincristine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Cefixime—Headache—Vincristine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Cefixime—Nausea—Carmustine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Cefixime—Vomiting—Mitoxantrone—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Cefixime—Rash—Mitoxantrone—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Cefixime—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Cefixime—Headache—Mitoxantrone—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Cefixime—Nausea—Vincristine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Cefixime—Nausea—Mitoxantrone—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Cefixime—Leukopenia—Methotrexate—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Cefixime—Convulsion—Methotrexate—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Cefixime—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Cefixime—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Cefixime—Dyspepsia—Methotrexate—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Cefixime—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Cefixime—Urticaria—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Cefixime—Abdominal pain—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Cefixime—Body temperature increased—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Cefixime—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Cefixime—Pruritus—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Cefixime—Diarrhoea—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Cefixime—Dizziness—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Cefixime—Vomiting—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Cefixime—Rash—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Cefixime—Dermatitis—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Cefixime—Headache—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Cefixime—Nausea—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
